Publikationen in Zusammenarbeit mit Forschern von University of Michigan Medical School (24)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  3. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2023

  1. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    Blood, Vol. 141, Núm. 9, pp. 1047-1059

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential

    British Journal of Cancer, Vol. 126, Núm. 11, pp. 1595-1603

  3. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Mortality prediction in chronic obstructive pulmonary disease comparing the gold 2015 and gold 2019 staging: A pooled analysis of individual patient data

    ERJ Open Research, Vol. 6, Núm. 4, pp. 1-10

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

2016

  1. miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation

    Journal of Molecular and Cellular Cardiology, Vol. 99, pp. 162-173

2015

  1. Characterization of large structural genetic mosaicism in human autosomes

    American Journal of Human Genetics, Vol. 96, Núm. 3, pp. 487-497

  2. Consensus nomenclature for CD8+ T cell phenotypes in cancer

    OncoImmunology, Vol. 4, Núm. 4

2013

  1. A prognostic DNA methylation signature for stage I non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 32, pp. 4140-4147

2012

  1. A diffusion-weighted magnetic resonance imaging-based study of transcervical carotid stenting with flow reversal versus transfemoral filter protection

    Journal of Vascular Surgery, Vol. 56, Núm. 6, pp. 1585-1590

2010

  1. A Prospective Evaluation of Cerebral Infarction following Transcervical Carotid Stenting with Carotid Flow Reversal

    European Journal of Vascular and Endovascular Surgery, Vol. 39, Núm. 6, pp. 661-666

2003

  1. Intrapulmonary expression of macrophage inflammatory protein 1α (CCL3) induces neutrophil and NK cell accumulation and stimulates innate immunity in murine bacterial pneumonia

    Infection and Immunity, Vol. 71, Núm. 3, pp. 1306-1315

2002

  1. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation

    Journal of Biological Chemistry, Vol. 277, Núm. 44, pp. 41701-41705